GLIPR1L1 Inhibitors
Chemical inhibitors of GLIPR1L1 target various aspects of cellular function to exert their inhibitory effects on the protein. Palmitic acid and cholesterol, for instance, incorporate into cellular membranes, altering membrane fluidity and receptor localization. GLIPR1L1's functional activity is closely tied to its position and behavior within specific membrane domains; thus, changes in the lipid composition of these membranes, as induced by these chemicals, can result in the inhibition of GLIPR1L1. GW4869 acts by inhibiting sphingomyelinase, which leads to an imbalance in the levels of sphingomyelin and ceramide, crucial components of cellular membranes that aid in the proper function of GLIPR1L1. Similarly, U18666A disrupts intracellular cholesterol transport and storage, leading to disruptions in lipid rafts that are essential for GLIPR1L1's activity. Manumycin A and Perillyl alcohol take a different approach by inhibiting the prenylation process of small GTPases and Ras proteins, respectively. This inhibition leads to a disruption in the signaling pathways that are necessary for the operational functionality of GLIPR1L1.
Continuing with the theme of lipid interactions, Simvastatin and Lovastatin inhibit the enzyme HMG-CoA reductase, which is a critical step in cholesterol synthesis. By limiting cholesterol production, these statins indirectly inhibit GLIPR1L1 by disrupting the lipid rafts that contribute to its proper functioning. D609 takes aim at phosphatidylcholine-specific phospholipase C, thereby altering diacylglycerol production, a lipid messenger integral to GLIPR1L1-related pathways. Filipin and Methyl-β-cyclodextrin work by directly binding to cholesterol, with Filipin also binding to ergosterol. This binding disrupts the structural integrity of lipid rafts, which consequently inhibits the function of GLIPR1L1 located within these domains. Lastly, Nystatin, by disrupting membrane integrity through its binding to ergosterol, indirectly inhibits GLIPR1L1 activity by affecting the membrane-bound processes and signaling pathways with which GLIPR1L1 is associated. Each chemical, through its unique interaction with cellular components and signaling pathways, contributes to the functional inhibition of GLIPR1L1.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palmitic Acid | 57-10-3 | sc-203175 sc-203175A | 25 g 100 g | $112.00 $280.00 | 2 | |
Palmitic acid can inhibit GLIPR1L1 by incorporating into cellular membranes and affecting membrane fluidity and signaling pathways. GLIPR1L1 requires specific membrane interactions for its function, and alterations in membrane composition can inhibit its activity. | ||||||
Cholesterol | 57-88-5 | sc-202539C sc-202539E sc-202539A sc-202539B sc-202539D sc-202539 | 5 g 5 kg 100 g 250 g 1 kg 25 g | $26.00 $2754.00 $126.00 $206.00 $572.00 $86.00 | 11 | |
Cholesterol can inhibit GLIPR1L1 by modulating membrane fluidity and receptor localization. GLIPR1L1 activity is dependent on its localization within membrane domains, which can be disrupted by changes in cholesterol levels. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 inhibits GLIPR1L1 by inhibiting sphingomyelinase, which alters the levels of sphingomyelin and ceramide in membranes. These lipids are important for membrane microdomains that are essential for the function of GLIPR1L1. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $140.00 $500.00 | 2 | |
U18666A can inhibit GLIPR1L1 by disrupting intracellular cholesterol transport and accumulation, which in turn can alter membrane microdomains where GLIPR1L1 is active. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $215.00 $622.00 | 5 | |
Manumycin A inhibits GLIPR1L1 by inhibiting Ras farnesyltransferase, leading to decreased prenylation of Ras, which affects signaling pathways necessary for GLIPR1L1 function. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Simvastatin inhibits GLIPR1L1 by inhibiting HMG-CoA reductase, leading to reduced cholesterol synthesis and subsequent disruption of lipid rafts necessary for GLIPR1L1 activity. | ||||||
D609 | 83373-60-8 | sc-201403 sc-201403A | 5 mg 25 mg | $185.00 $564.00 | 7 | |
D609 inhibits GLIPR1L1 by inhibiting phosphatidylcholine-specific phospholipase C, which alters the production of diacylglycerol, an important lipid messenger in pathways involving GLIPR1L1. | ||||||
Filipin III | 480-49-9 | sc-205323 sc-205323A | 500 µg 1 mg | $116.00 $145.00 | 26 | |
Filipin can inhibit GLIPR1L1 by binding to cholesterol, disrupting lipid rafts, and thereby inhibiting the proper localization and function of GLIPR1L1 within the plasma membrane. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Lovastatin inhibits GLIPR1L1 by inhibiting HMG-CoA reductase, which leads to reduced cholesterol levels, affecting membrane microdomains and GLIPR1L1 activity. | ||||||
Methyl-β-cyclodextrin | 128446-36-6 | sc-215379A sc-215379 sc-215379C sc-215379B | 100 mg 1 g 10 g 5 g | $25.00 $65.00 $170.00 $110.00 | 19 | |
Methyl-β-cyclodextrin inhibits GLIPR1L1 by extracting cholesterol from the plasma membrane, disrupting lipid rafts, and thus inhibiting the membrane-associated function of GLIPR1L1. | ||||||